bioMérieux Partners with First U.S. Hospital to Use VITEK® REVEAL™ Fast AST for Blood Stream Infections
bioMérieux is partnering with AdventHealth Orlando as they become the first institution to adopt the VITEK® REVEAL™ Fast Antimicrobial Susceptibility Testing (AST) System for clinical use in the United States. Bringing this innovative diagnostic solution into the U.S. hospital setting helps healthcare professionals improve patient care by equipping them with the resources to provide more precise, faster results while advancing the fight against antimicrobial resistance.
The modular VITEK REVEAL Fast AST System can deliver actionable antimicrobial susceptibility results for gram-negative bacteria directly from positive blood cultures in an average of 5.5-6 hours1, 2 enabling same-day treatment decision-making for patients suffering from blood stream infections.
Given that 11 million people worldwide die of sepsis3 and 1.3 million deaths are attributable to antibiotic-resistant bacteria4, fast and accurate AST results and interpretation are critical for clinicians to rapidly optimize therapy, more effectively prescribe antibiotics, and improve patient outcomes.
“While VITEK REVEAL is already being utilized in labs across the world, providing this solution to clinicians in a U.S. hospital environment drives bioMérieux’s commitment to antimicrobial stewardship. Through this partnership with AdventHealth Orlando, we are working together to leverage clinical innovation and clinical expertise to support physicians in their timely treatment of patients and to appropriately target antibiotic prescriptions in urgent situations. ”
In patients with sepsis, the risk of mortality increases 9%5 every hour between presentation and antibiotic administration. By pioneering the U.S. use of VITEK REVEAL AST System, AdventHealth Orlando is able to offer fast AST results to accelerate the treatment of bloodstream infections and promote responsible antimicrobial use.
"Integrating VITEK REVEAL for fast AST into the blood culture workflow addresses a critical clinical need for modern microbiology labs. Combined with blood culture identification (BCID), it can provide fast and clinically actionable results, which could directly improve patient care, laboratory efficiency, and antimicrobial stewardship. This innovative approach embodies AdventHealth's commitment to whole-person care through leading-edge technology, personalized healthcare, and compassionate patient management," said Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, clinical microbiologist and director of microbiology, virology and immunology at AdventHealth, Orlando.
1 Rottman M, Rhodes PA, Singh P, Herrmann JL, Jeannot K, Cattoir V, Carbonnelle E, Plesiat P, Williams A, Dortet L. Clinical evaluation of the SPECIFIC REVEAL™ Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England. Poster presented at: 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); 2022 May; Lisbon, Portugal.
2 BMX.1.129899 Clinical Trial Summary Report (proprietary, on file at bioMerieux).
3 Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet (London, England). 2020;395(10219):200-11.
4 Murray CJ. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet. 2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0.
5 Liu VX et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Respir Crit Care Med. 2017 Oct 1;196(7):856–863.
